Cholangiocarcinoma (CCA), a malignant tumor of the biliary epithelium, is a tumor with an ineffective diagnosis and poor prognosis. We have previously identified an overexpression of orosomucoid 2(ORM2) along with CCA development in hamsters using a proteomics technique.
OBJECTIVE:
To evaluate plasma ORM2 as a candidate risk biomarker for CCA in humans.
METHODS:
Overexpression of ORM2 in CCA patients was assessed by western blotting and immunohistochemistry. The diagnostic efficacy of ORM2 was investigated in the plasma of patients with hepatobiliary diseases - including 46 cholangitis patients and 70 CCA patients - compared with 20 healthy individuals, using enzyme-linked immunosorbent assay (ELISA).
RESULTS:
Overexpression of ORM2 was observed in the cytoplasm of bile duct tumor cells and in the adjacent normal hepatocytes at a much higher intensity than in normal bile duct cells. Western blot analysis revealed that its expression was significantly higher in the plasma of CCA patients compared with that of healthy individuals (P < 0.01). ELISA showed that plasma ORM2 levels were significantly elevated in CCA and cholangitis groups compared with healthy individuals (P < 0.0001). The sensitivity and specificity of ORM2 in distinguishing CCA patients from healthy patients were 92.86% and 73.68%, respectively.
CONCLUSIONS:
Plasma ORM2 could serve as a new risk marker for CCA.
ShinH.R., OhJ.K., MasuyerE., CuradoM.P., BouvardV., FangY.Y., WiangnonS., SripaB. and HongS.T., Epidemiology of cholangiocarcinoma: An update focusing on risk factors, Cancer Sci101 (2010), 579-585.
2.
SripaB. and PairojkulC., Cholangiocarcinoma: lessons from Thailand, Curr Opin Gastroenterol24 (2008), 349-356.
3.
BonneyG.K., CravenR.A., PrasadR., MelcherA.F., SelbyP.J. and BanksR.E., Circulating markers of biliary malignancy: opportunities in proteomics?Lancet Oncol9 (2008), 149-158.
4.
PatelT., Cholangiocarcinoma-controversies and challenges, Nat Rev Gastroenterol Hepatol8 (2011), 189-200.
5.
PattanathienP., KhuntikeoN., PromthetS. and Kamsa-ArdS., Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand, Asian Pac J Cancer Prev14 (2013), 321-324.
6.
SriputthaS., KhuntikeoN., PromthetS. and Kamsa-ArdS., Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand, Asian Pac J Cancer Prev14 (2013), 1107-1110.
7.
QinX.L., WangZ.R., ShiJ.S., LuM., WangL. and HeQ.R., Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA, World J Gastroenterol10 (2004), 427-432.
8.
SrinivasP.R., VermaM., ZhaoY. and SrivastavaS., Proteomics for cancer biomarker discovery, Clin Chem48 (2002), 1160-1169.
9.
RucksakenR., KhoontawadJ., RoytrakulS., PinlaorP., HirakuY., WongkhamC., PairojkulC., BoonmarsT. and PinlaorS., Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma, Cancer Biomark12 (2012), 81-95.
10.
CecilianiF. and PocacquaV., The acute phase protein alpha1-acid glycoprotein: A model for altered glycosylation during diseases, Curr Protein Pept Sci8 (2007), 91-108.
11.
BaumannH. and GauldieJ., Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation, Mol Biol Med7 (1990), 147-159.
12.
ZhangX., XiaoZ., LiuX., DuL., WangL., WangS., ZhengN., ZhengG., LiW., DongZ., ZhuangX. and WangC., The potential role of ORM2 in the development of colorectal cancer, PLoS One7 (2012), e31868.
13.
BachtiarI., SantosoJ.M., AtmanegaraB., GaniR.A., HasanI., LesmanaL.A., SulaimanA., GuJ. and TaiS., Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma, Clin Chim Acta399 (2009), 97-101.
14.
YongvanitP., PinlaorS. and BartschH., Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis, Parasitol Int61 (2012), 130-135.
15.
DeOliveiraM.L., CunninghamS.C., CameronJ.L., KamangarF., WinterJ.M., LillemoeK.D., ChotiM.A., YeoC.J. and SchulickR.D., Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann Surg245 (2007), 755-762.
16.
LazaridisK.N. and GoresG.J., Primary sclerosing cholangitis and cholangiocarcinoma, Semin Liver Dis26 (2006), 42-51.
17.
BjornssonE., KilanderA. and OlssonR., CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis, Liver19 (1999), 501-508.
18.
EhlkenH. and SchrammC., Primary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics, Dig Dis31 (2013), 118-125.
19.
SinakosE., SaengerA.K., KeachJ., KimW.R. and LindorK.D., Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma, Clin Gastroenterol Hepatol9 (2011), 434-439e431.
20.
TysonG.L. and El-SeragH.B., Risk factors for cholangiocarcinoma, Hepatology54 (2011), 173-184.
MagidE., GuldagerH., HesseD. and ChristiansenM.S., Monitoring urinary orosomucoid in acute inflammation: observations on urinary excretion of orosomucoid, albumin, alpha1-microglobulin, and IgG, Clin Chem51 (2005), 2052-2058.
24.
TsutsumiM. and TakaseS., Usefulness of microheterogeneity of serum alpha 1-acidglycoprotein as a marker for alcohol abuse, Alcohol25 (2001), 181-184.
25.
Van Den HeuvelM.M., PolandD.C., De GraaffC.S., HoefsmitE.C., PostmusP.E., BeelenR.H. and Van DijkW., The degree of branching of the glycans of alpha(1)-acid glycoprotein in asthma. A correlation with lung function and inflammatory parameters, Am J Respir Crit Care Med161 (2000), 1972-1978.
26.
Romao Jr.J.E., HaiashiA.R., EliasR.M., LudersC., FerraboliR., CastroM.C. and AbensurH., Positive acute-phase inflammatory markers in different stages of chronic kidney disease, Am J Nephrol26 (2006), 59-66.
27.
IrmakS., TilkiD., HeukeshovenJ., Oliveira-FerrerL., FriedrichM., HulandH. and ErgunS., Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer, Proteomics5 (2005), 4296-4304.
28.
OchiY., Studies on immunological characteristic of CEA-CEA may be a biosynthetic precursor of alpha 1-acid glycoprotein-, Gan To Kagaku Ryoho10 (1983), 585-594.
29.
OchiY., FujiyamaY., HosodaS., MiyazakiT., YoshimuraM., HachiyaT. and KajitaY., Immunological similarity of CEA with alpha 1-acid glycoprotein (orosomucoid), Clin Chim Acta122 (1982), 145-160.
30.
DubeJ.Y., ParadisG., TetuB. and TremblayR.R., Synthesis of alpha 1-acid glycoprotein by the human prostate, Prostate15 (1989), 251-258.
31.
NgR.C., RobertsA.N., WilsonR.G., LatnerA.L. and TurnerG.A., Analyses of protein extracts of human breast cancers: changes in glycoprotein content linked to the malignant phenotype, Br J Cancer55 (1987), 249-254.
32.
YamamotoM., TakasakiK., YoshikawaT., UenoK. and NakanoM., Does gross appearance indicate prognosis in intrahepatic cholangiocarcinoma?J Surg Oncol69 (1998), 162-167.
33.
GuglielmiA., RuzzenenteA., CampagnaroT., PacheraS., ValdegamberiA., NicoliP., CappellaniA., MalfermoniG. and IaconoC., Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection, World J Surg33 (2009), 1247-1254.
